JAPAN BREAST CANCER RESEARCH GROUP
🇯🇵Japan
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Phase 3
- Conditions
- Interventions
- First Posted Date
- 2017-08-29
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 480
- Registration Number
- NCT03264547
- Locations
- 🇯🇵
National Hospital Organization Osaka National Hospital, Ōsaka, Osaka, Japan
🇯🇵Kanagawa Cancer Center, Yokohama, Kanagawa, Japan
A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer
- First Posted Date
- 2015-08-04
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 370
- Registration Number
- NCT02514681
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
🇯🇵Kumamoto University Hospital, Kumamoto City, Kumamoto, Japan
🇯🇵Aichi Cancer Center, Chikusa-ku, Aichi, Japan
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-21
- Last Posted Date
- 2022-08-04
- Lead Sponsor
- Japan Breast Cancer Research Group
- Target Recruit Count
- 160
- Registration Number
- NCT01989780
- Locations
- 🇯🇵
Japan Breast Cancer Research Group, Chuo-ku, Nihonbashi, Koami-cho, Tokyo, Japan
© Copyright 2024. All Rights Reserved by MedPath